Capricor Therapeutics Inc (OTCMKTS:CAPR) had its price objective lifted by research analysts at HC Wainwright from $2.15 to $6.50 in a research note issued to investors on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock.
Several other research firms have also recently weighed in on CAPR. Rodman & Renshaw reiterated a “buy” rating and issued a $2.15 price objective on shares of Capricor Therapeutics in a report on Saturday, July 22nd. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Wednesday, August 16th. Finally, ValuEngine cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $5.48.
Shares of Capricor Therapeutics (CAPR) opened at 1.00 on Friday. Capricor Therapeutics has a one year low of $0.63 and a one year high of $3.99. The firm has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.72. The company’s market capitalization is $22.60 million.
Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $1.10 million. Equities analysts forecast that Capricor Therapeutics will post ($0.70) earnings per share for the current year.
An institutional investor recently raised its position in Capricor Therapeutics stock. Virtu KCG Holdings LLC lifted its position in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 571.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 179,301 shares of the biotechnology company’s stock after acquiring an additional 152,614 shares during the period. Virtu KCG Holdings LLC owned 0.79% of Capricor Therapeutics worth $149,000 as of its most recent SEC filing.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.